Creating new treatments for antibiotic-resistant bacteria
Official title: Development of Therapeutic Products for Antibiotic Resistant Bacteria
Funded at Venatorx Pharmaceuticals, INC. · NIH-11132566 · Data updated 2026-11-12
This study is working on creating new treatments to help fight infections caused by antibiotic-resistant bacteria, so that patients can have better options when current antibiotics don't work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Venatorx Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Malvern, United States) |
| Project start | July 1, 2020 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $9,407,873 |
| NIH project number | 75N93020C00016-P00008-9999-1 |
| Project ID | NIH-11132566 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals suffering from infections that are resistant to standard antibiotic treatments.
✕Less likely to help
Patients with infections that are not caused by antibiotic-resistant bacteria may not receive any benefit from this research.
What this research studies
This research focuses on developing new therapeutic products to combat antibiotic-resistant bacteria, which pose a significant threat to public health. The approach includes optimizing lead compounds, selecting the best candidates for further development, and conducting preclinical studies to ensure safety and efficacy. Patients may benefit from innovative treatments that could effectively target infections caused by resistant bacteria, which are often difficult to treat with existing antibiotics.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Other research has shown promise in developing new therapies for antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
-
Venatorx Pharmaceuticals, INC.
Malvern, United States Active
Researchers
- Principal investigator: Pevear, Daniel — Venatorx Pharmaceuticals, INC.
- Study coordinator: Pevear, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.